If there's anything that I find a bit puzzling, it's that neither Brilacidin nor Kevetrin has been in any general wide-spread news story (NYT, WSJ, Boston Globe, Sci Am, AFP or AP news service, etc.) I suppose it's too early for Kevetrin, but given it's P53 action I think its novelty and potential outweigh that argument. And Brilacidin.... how is this not front page news now, after that brilliant Phase 2b? Can't come up with any argument for that.
Puzzling to me.
Market Data 
Markets 
AI
